柏柏林化物改善了亚慢性和慢性中毒患者的认知功能和海马体抗氧化状态
Fatemeh Zare Mehrjerdi1, Azadeh Shahrokhi Raeini2, Fatemeh Sadate Zebhi2
1Yazd Neuroendocrine Research Center, School of Medicine, Shahid Sadoughi University of Medical Sciences and Health Services, Yazd, 8915133149, Iran. mehzaref@gmail.com.
Chinese journal of integrative medicine
|September 7, 2024
概括
柏柏林化物 (BBR) 保护大鼠免受引起的认知障碍和海马损伤. BBR显示出抗氧化能力,改善氧化应激和海马细胞密度.
科学领域:
- 神经科学是一个神经科学.
- 毒理学 毒理学 毒理学
- 药理学 药理学是指药理学的学科.
背景情况:
- 暴露是一种显著的神经毒剂,特别影响海马.
- 中毒可能导致认知缺陷和大脑中的氧化应激.
- 海马对于学习和记忆至关重要,因此容易受到引起的损伤.
研究的目的:
- 在大鼠模型中研究贝贝林化物 (BBR) 对诱导的海马损伤的神经保护作用.
- 评估BBR对暴露于的老鼠空间学习,记忆和氧化应激标志物的影响.
主要方法:
- 维斯塔鼠被暴露在乙酸盐 (100和500ppm) 中1到2个月.
- 鼠每天接受BBR (50 mg/kg) 的腹腔内注射.
- 使用莫里斯水迷宫评估了空间学习和记忆;分析了海马体组织的组织学变化,抗氧化酶活性 (catalase,超氧化物转化酶,谷氨过氧化酶) 和甲水平.
主要成果:
- 在暴露于的老鼠中,BBR显著降低了认知障碍.
- 暴露增加了海马体的氧化应激 (抗氧化剂减少,脂质过氧化增加),BBR治疗显著改善了这种情况.
- 给BBR增加了健康海马细胞的密度,特别是在暴露于2个月的老鼠中.
结论:
- 柏柏林化物对大鼠的诱导的海马损伤和认知功能障碍表现出显著的神经保护作用.
- 研究结果表明,BBR的抗氧化性质有助于它减轻海马中毒性的能力.
相关概念视频
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
110
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
110
Role of Neurotransmitters in Memory
485
Neurotransmitters are integral to the brain's communication system, enabling neurons to transmit signals across synapses. This chemical exchange underpins various cognitive functions, including memory processes. The role of neurotransmitters in memory is multifaceted, influencing the encoding, consolidation, and retrieval of memories through their action on different neural circuits.
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...
485
Alzheimer's Disease: Treatment
170
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
170
Alzheimer's Disease: Overview
454
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
454
Long-term Depression
2.5K
Long-term depression, or LTD, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTD is the process of synaptic weakening that occurs over time between pre and postsynaptic neuronal connections. The synaptic weakening of LTD works in opposition to synaptic strengthening by long-term potentiation (LTP) and together are the main mechanisms that underlie learning and memory.
Calcium Ion Concentration Mechanism
If over...
Calcium Ion Concentration Mechanism
If over...
2.5K


